Regular packed cell transfusion in patients with thalassemia major leads to iron overload. Chelation therapy is one of the important aspects of thalassemia care as iron overload causes significant cardiac, hepatic, and endocrine dysfunction. We report a case of thalassemia major with severe iron overload causing cardiac and liver dysfunction who benefitted from triple drug chelation therapy. Tr...

thalassemia is the most prevalent genetic disorder in iran and around the world and these patients need regular careful care. the present study reports results of routine examination of patients visited thalassemia clinic of tehran. data about clinical and laboratory examinations of 413 thalassemic were extracted and analyzed. the prevalence of heart complications, diabetes, growth retardation,...

background: cadmium (cd) is an extremely toxic metal and environmental exposure to cd has been particularly problematic in the world. oral exposure to cd may result in adverse effects on a number of tissues, the immune system, and the cardiovascular system. compounds containing cd are also carcinogenic. the presence of cd in drinking water resources in the southeastern region of rafsanjan plain...

Chelation therapy is thought to not only remove contaminating metals but also to decrease free radical production. However, in standard ethylene diamine tetracetic acid (EDTA) chelation therapy, high doses of vitamin C with potential pro-oxidant effects are often added to the chelation solution. The authors demonstrated previously that the intravenous administration of the standard chelation co...

BACKGROUND Understanding patients' views about medication is crucial to maximize adherence. Thalassemia is a congenital blood disorder requiring chronic blood transfusions and daily iron chelation therapy. METHODS The Beliefs in Medicine Questionnaire (BMQ) was used to assess beliefs in chelation in thalassemia patients from North America and London in the Thalassemia Longitudinal Cohort (TLC...

BACKGROUND Previous research suggest that repeated lead-chelation therapy decelerates progression of renal insufficiency in non-diabetic (non-DM) patients with high-normal body lead burden (BLB). Study findings are limited by relatively short-term follow-up and small sample size. METHODS A total of 116 non-DM patients with chronic kidney diseases (serum creatinine level of 1.5-3.9 mg/dl), hig...